Enzaplatovir clinical trials
Also written BTA585.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses enzaplatovir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Biota Pharmaceuticals, Inc. (2) · Biota Pharma Europe Limited (1)
Studies
Open first, then newest update. How each study uses enzaplatovir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy VolunteersCompletedPhase 1Biota Pharmaceuticals, Inc.NCT02668367Written as BTA-C585 oral capsules
- Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy VolunteersCompletedPhase 1Biota Pharmaceuticals, Inc.NCT02558413Written as BTA-C585 oral capsules
- Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge StudyCompletedPhase 2Biota Pharma Europe LimitedNCT02718937Written as BTA-C585 oral capsule
Codes
What other systems call enzaplatovir · ClinicalTrials.gg INT001697
- MeSH (NLM) C000718869enzaplatovirOne source NLM
- UNII (FDA) OZ40XB915EENZAPLATOVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q27285922enzaplatovirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174819EnzaplatovirOne source FDA
- DrugBank DB21042One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718869 | enzaplatovir | One source NLM |
| UNII (FDA) | OZ40XB915E | ENZAPLATOVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27285922 | enzaplatovir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174819 | Enzaplatovir | One source FDA |
| DrugBank | DB21042 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.